140 related articles for article (PubMed ID: 30100060)
1. Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway.
Yang Z; Tao Y; Xu X; Cai F; Yu Y; Ma L
Biochem Biophys Res Commun; 2018 Sep; 503(3):2124-2131. PubMed ID: 30100060
[TBL] [Abstract][Full Text] [Related]
2. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway.
Gai JQ; Sheng X; Qin JM; Sun K; Zhao W; Ni L
Int J Oncol; 2016 Jan; 48(1):338-48. PubMed ID: 26648168
[TBL] [Abstract][Full Text] [Related]
3. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways.
Chen YY; Lu HF; Hsu SC; Kuo CL; Chang SJ; Lin JJ; Wu PP; Liu JY; Lee CH; Chung JG; Chang JB
Environ Toxicol; 2015 Jan; 30(1):74-82. PubMed ID: 23949904
[TBL] [Abstract][Full Text] [Related]
4. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells.
Qiu DZ; Zhang ZJ; Wu WZ; Yang YK
BMC Complement Altern Med; 2013 Jul; 13():185. PubMed ID: 23870199
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
6. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
[TBL] [Abstract][Full Text] [Related]
7. Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin.
Sheng X; Zhu P; Zhao Y; Zhang J; Li H; Zhao H; Qin J
Recent Pat Anticancer Drug Discov; 2021; 16(1):54-65. PubMed ID: 33530915
[TBL] [Abstract][Full Text] [Related]
8. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice.
Zhang ZJ; Yang YK; Wu WZ
J Transl Med; 2014 Feb; 12():57. PubMed ID: 24581171
[TBL] [Abstract][Full Text] [Related]
9. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
10. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
11. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells.
Tsai SC; Yang JS; Peng SF; Lu CC; Chiang JH; Chung JG; Lin MW; Lin JK; Amagaya S; Wai-Shan Chung C; Tung TT; Huang WW; Tseng MT
Int J Oncol; 2012 Oct; 41(4):1431-42. PubMed ID: 22858649
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway.
Li D; Zhang B; Hu C
Acta Biochim Biophys Sin (Shanghai); 2017 Jul; 49(7):581-587. PubMed ID: 28475688
[TBL] [Abstract][Full Text] [Related]
13. SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma.
Zhang Z; Yan Z; Yuan Z; Sun Y; He H; Mai C
Tumour Biol; 2015 Mar; 36(3):1503-9. PubMed ID: 25537088
[TBL] [Abstract][Full Text] [Related]
14. The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin.
Sheng X; Zhu P; Qin J; Li Q
Oncol Rep; 2018 Jun; 39(6):2931-2941. PubMed ID: 29658591
[TBL] [Abstract][Full Text] [Related]
15. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase.
Yu Z; Feng H; Sun X; Zhuo Y; Li M; Zhou Z; Huang L; Jiang Y; Zhu X; Zhang X; Le F; Zheng C; Cheng AS; Gao Y
Sci Rep; 2018 Mar; 8(1):3891. PubMed ID: 29497076
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-related hepatocellular carcinoma.
Yang Z; Zhuang L; Yu Y; Zhou W; Lu Y; Xu Q; Tang B; Chen X
Discov Med; 2015 Dec; 20(112):349-56. PubMed ID: 26760979
[TBL] [Abstract][Full Text] [Related]
17. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells.
Hsu CM; Tsai Y; Wan L; Tsai FJ
Int J Oncol; 2013 Jul; 43(1):338-48. PubMed ID: 23677253
[TBL] [Abstract][Full Text] [Related]
18. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways.
Qi F; Inagaki Y; Gao B; Cui X; Xu H; Kokudo N; Li A; Tang W
Cancer Sci; 2011 May; 102(5):951-8. PubMed ID: 21288283
[TBL] [Abstract][Full Text] [Related]
19. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
